Literature DB >> 34341736

Biphasic GA 68-labeled prostate specific membrane antigen-11 positron emission tomography/computed tomography scans in the differential diagnosis and risk stratification of initial primary prostate cancer.

Lu-Ping Qin1, Jie Lv1,2, Ming-Zhao Li3, Liang-Jun Xie1, Jin-Ping Li1, Jian-Fang Li1, Mu-Hua Cheng1.   

Abstract

BACKGROUND: This study aimed to assess the value of biphasic GA 68-labeled prostate-specific membrane antigen-11 (68Ga-PSMA-11) positron emission tomography/computed tomography (PET/CT) scan in the differential diagnosis and risk stratification of initial primary prostate cancer (PCa).
METHODS: A total of 51 patients with PCa (8 low- and intermediate-risk PCa patients and 43 high-risk PCa patients) and 36 patients with benign prostate lesions, who underwent standard whole-body imaging and delayed pelvic imaging of 68Ga-PSMA-11 PET/CT, were enrolled in this prospective study. The PET parameters, such as maximum and mean standard uptake value (SUVmax and SUVmean), and maximum and mean standard retention index of PET images were calculated and compared in different prostate lesions. The diagnostic performances of the PET parameters were evaluated by receiver operating characteristic (ROC) curves.
RESULTS: All the PET parameters of PCa participants were significantly higher than those of participants with benign prostate lesions (P<0.001). The SUVmean of delayed imaging had the best performance in the diagnosis of PCa with an area under the curve (AUC) of 0.918 (95% CI: 0.858 to 0.977), the sensitivity of 90.0%, and specificity of 83.3%. The SUVmax and SUVmean of high-risk PCa participants were significantly higher than those of low- and intermediate-risk PCa participants (P<0.005). The SUVmax of standard imaging had the best performance in predicting high-risk PCa with an AUC of 0.890 (95% CI: 0.799 to 0.980), a sensitivity of 76.7%, and a specificity of 100.0%.
CONCLUSIONS: The biphasic 68Ga-PSMA-11 PET/CT scan had good performance in discriminating prostate cancer from benign prostate diseases. The SUVmean of the prostate lesion at delayed imaging of 68Ga-PSMA-11 PET/CT had the best value in the differential diagnosis of PCa, and the SUVmax at standard imaging was most valuable in predicting the risk stratification of PCa. 2021 Quantitative Imaging in Medicine and Surgery. All rights reserved.

Entities:  

Keywords:  68Ga-PSMA-11; Initial prostate cancer; differential diagnosis; diphase; risk stratification

Year:  2021        PMID: 34341736      PMCID: PMC8245961          DOI: 10.21037/qims-20-1312

Source DB:  PubMed          Journal:  Quant Imaging Med Surg        ISSN: 2223-4306


  23 in total

1.  Global, Regional and National Burden of Prostate Cancer, 1990 to 2015: Results from the Global Burden of Disease Study 2015.

Authors:  Farhad Pishgar; Hedyeh Ebrahimi; Sahar Saeedi Moghaddam; Christina Fitzmaurice; Erfan Amini
Journal:  J Urol       Date:  2017-11-09       Impact factor: 7.450

2.  Diagnostic performance of 68Ga-PSMA PET/CT in the detection of prostate cancer prior to initial biopsy: comparison with cancer-predicting nomograms.

Authors:  Jingliang Zhang; Shuai Shao; Peng Wu; Daliang Liu; Bo Yang; Donghui Han; Yu Li; Xiaoyu Lin; Wei Song; Milin Cao; Jing Zhang; Fei Kang; Weijun Qin; Jing Wang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-01-11       Impact factor: 9.236

3.  68Ga-PSMA PET/CT better characterises localised prostate cancer after MRI and transperineal prostate biopsy: Is 68Ga-PSMA PET/CT guided biopsy the future?

Authors:  Peter Donato; Andrew Morton; John Yaxley; Sachinka Ranasinghe; Patrick E Teloken; Samuel Kyle; Geoff Coughlin; Rachel Esler; Nigel Dunglison; Robert A Gardiner; Matthew J Roberts
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-01-07       Impact factor: 9.236

4.  Multiple Time-Point 68Ga-PSMA I&T PET/CT for Characterization of Primary Prostate Cancer: Value of Early Dynamic and Delayed Imaging.

Authors:  Sebastian Schmuck; Martin Mamach; Florian Wilke; Christoph A von Klot; Christoph Henkenberens; James T Thackeray; Jan M Sohns; Lilli Geworski; Tobias L Ross; Hans-Juergen Wester; Hans Christiansen; Frank M Bengel; Thorsten Derlin
Journal:  Clin Nucl Med       Date:  2017-06       Impact factor: 7.794

5.  Multiphasic 68Ga-PSMA PET/CT in the Detection of Early Recurrence in Prostate Cancer Patients with a PSA Level of Less Than 1 ng/mL: A Prospective Study of 135 Patients.

Authors:  Mohsen Beheshti; Reyhaneh Manafi-Farid; Hans Geinitz; Reza Vali; Wolfgang Loidl; Felix M Mottaghy; Werner Langsteger
Journal:  J Nucl Med       Date:  2020-02-14       Impact factor: 10.057

6.  EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.

Authors:  Nicolas Mottet; Joaquim Bellmunt; Michel Bolla; Erik Briers; Marcus G Cumberbatch; Maria De Santis; Nicola Fossati; Tobias Gross; Ann M Henry; Steven Joniau; Thomas B Lam; Malcolm D Mason; Vsevolod B Matveev; Paul C Moldovan; Roderick C N van den Bergh; Thomas Van den Broeck; Henk G van der Poel; Theo H van der Kwast; Olivier Rouvière; Ivo G Schoots; Thomas Wiegel; Philip Cornford
Journal:  Eur Urol       Date:  2016-08-25       Impact factor: 20.096

Review 7.  When should we recommend use of dual time-point and delayed time-point imaging techniques in FDG PET?

Authors:  Gang Cheng; Drew A Torigian; Hongming Zhuang; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-01-30       Impact factor: 9.236

8.  Biphasic ⁶⁸Ga-PSMA-HBED-CC-PET/CT in patients with recurrent and high-risk prostate carcinoma.

Authors:  Carsten-Oliver Sahlmann; Birgit Meller; Caroline Bouter; Christian Oliver Ritter; Philipp Ströbel; Joachim Lotz; Lutz Trojan; Johannes Meller; Sameh Hijazi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-11-12       Impact factor: 9.236

9.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

10.  Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer.

Authors:  Matthias Eder; Oliver Neels; Miriam Müller; Ulrike Bauder-Wüst; Yvonne Remde; Martin Schäfer; Ute Hennrich; Michael Eisenhut; Ali Afshar-Oromieh; Uwe Haberkorn; Klaus Kopka
Journal:  Pharmaceuticals (Basel)       Date:  2014-06-30
View more
  1 in total

Review 1.  The Role of PSMA PET/CT in the Primary Diagnosis and Follow-Up of Prostate Cancer-A Practical Clinical Review.

Authors:  Anna Rebecca Lisney; Conrad Leitsmann; Arne Strauß; Birgit Meller; Jan Alexander Bucerius; Carsten-Oliver Sahlmann
Journal:  Cancers (Basel)       Date:  2022-07-26       Impact factor: 6.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.